PMID- 38399244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 16
IP  - 2
DP  - 2024 Jan 28
TI  - Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.
LID - 10.3390/pharmaceutics16020183 [doi]
LID - 183
AB  - The success of long-acting (LA) drug delivery systems (DDSs) is linked to their 
      biocompatible polymers. These are used for extended therapeutic release. For 
      treatment or prevention of human immune deficiency virus type one (HIV-1) 
      infection, LA DDSs hold promise for improved regimen adherence and reduced 
      toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is 
      safe and effective. Alternative promising DDSs include implants, prodrugs, 
      vaginal rings, and microarray patches. Each can further meet patients' needs. We 
      posit that the physicochemical properties of the formulation chemical design can 
      optimize drug release profiles. We posit that the strategic design of LA DDS 
      polymers will further improve controlled drug release to simplify dosing 
      schedules and improve regimen adherence.
FAU - Nayan, Mohammad Ullah
AU  - Nayan MU
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Panja, Sudipta
AU  - Panja S
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Sultana, Ashrafi
AU  - Sultana A
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Zaman, Lubaba A
AU  - Zaman LA
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Vora, Lalitkumar K
AU  - Vora LK
AUID- ORCID: 0000-0001-8106-9066
AD  - School of Pharmacy, Queen's University Belfast, Medical Biology Centre, Belfast 
      BT9 7BL, UK.
FAU - Sillman, Brady
AU  - Sillman B
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Gendelman, Howard E
AU  - Gendelman HE
AUID- ORCID: 0000-0002-7831-0370
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
FAU - Edagwa, Benson
AU  - Edagwa B
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, NE 68198-5880, USA.
LA  - eng
GR  - R01 NS034239; R01 NS036126; R01 MH115860; R01 NS126089 (HEG); R01 AI145542 (BE 
      and HEG); R01 AI158160 (HEG and BE)/NH/NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20240128
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10892262
OTO - NOTNLM
OT  - HIV
OT  - antiretroviral therapy
OT  - chronic infectious diseases
OT  - implants
OT  - long-acting formulations
OT  - microarray patches
OT  - polymer
OT  - prodrug nanoformulations
OT  - vaginal rings
COIS- The authors declare no conflict of interest.
EDAT- 2024/02/24 11:45
MHDA- 2024/02/24 11:46
PMCR- 2024/01/28
CRDT- 2024/02/24 01:18
PHST- 2023/12/23 00:00 [received]
PHST- 2024/01/19 00:00 [revised]
PHST- 2024/01/24 00:00 [accepted]
PHST- 2024/02/24 11:46 [medline]
PHST- 2024/02/24 11:45 [pubmed]
PHST- 2024/02/24 01:18 [entrez]
PHST- 2024/01/28 00:00 [pmc-release]
AID - pharmaceutics16020183 [pii]
AID - pharmaceutics-16-00183 [pii]
AID - 10.3390/pharmaceutics16020183 [doi]
PST - epublish
SO  - Pharmaceutics. 2024 Jan 28;16(2):183. doi: 10.3390/pharmaceutics16020183.